Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: Is it better than three dimensional conformal radiotherapy?

Radiation Oncology

Riccardo Maurizi Enrici²  Laura Chiacchiararelli¹  Giuseppe Minniti²  Mattia F Osti²  Maurizio Valeriani²  Maria Christina Cox⁴  Alessandro Fanelli²  Stefano Bracci²  Marco D’Arienzo³  Chiara Bolzan¹  Vitaliana De Sanctis² 

[1] Departments of Medical Physics, Sant’Andrea Hospital, Via di Grottarossa 1035/1039, 00189, Rome, Italy;Departments of Radiotherapy, Sant’Andrea Hospital, Via di Grottarossa 1035/1039, 00189, Rome, Italy;Centro Ricerche Casaccia, Istituto Nazionale di Metrologia delle Radiazioni Ionizzanti, ENEA, Via Anguillarese 301, 00123, Rome, Italy;Departments of Hematology, Sant’Andrea Hospital, Via di Grottarossa 1035/1039, 00189, Rome, Italy

关键词: NTCP;    3D-CRT;    IMRT;    Hodgkin;   

Others  :  1155474
DOI  :  10.1186/1748-717X-7-129

 received in 2012-02-13, accepted in 2012-06-18,  发布年份 2012

【 摘 要 】

Background

Cure rate of early Hodgkin Lymphoma are high and avoidance of late toxicities is of paramount importance. This comparative study aims to assess the normal tissue sparing capability of intensity-modulated radiation therapy (IMRT) versus standard three-dimensional conformal radiotherapy (3D-CRT) in terms of dose-volume parameters and normal tissue complication probability (NTCP) for different organs at risk in supradiaphragmatic Hodgkin Lymphoma (HL) patients.

Methods

Ten HL patients were actually treated with 3D-CRT and all treatments were then re-planned with IMRT. Dose-volume parameters for thyroid, oesophagus, heart, coronary arteries, lung, spinal cord and breast were evaluated. Dose-volume histograms generated by TPS were analyzed to predict the NTCP for the considered organs at risk, according to different endpoints.

Results

Regarding dose-volume parameters no statistically significant differences were recorded for heart and origin of coronary arteries. We recorded statistically significant lower V30 with IMRT for oesophagus (6.42 vs 0.33, p = 0.02) and lungs (4.7 vs 0.1 p = 0.014 for the left lung and 2.59 vs 0.1 p = 0.017 for the right lung) and lower V20 for spinal cord (17.8 vs 7.2 p = 0.02). Moreover the maximum dose to the spinal cord was lower with IMRT (30.2 vs 19.9, p <0.001). Higher V10 with IMRT for thyroid (64.8 vs 95, p = 0.0019) and V5 for lungs (30.3 vs 44.8, p = 0.03, for right lung and 28.9 vs 48.1, p = 0.001 for left lung) were found, respectively. Higher V5 and V10 for breasts were found with IMRT (V5: 4.14 vs 20.6, p = 0.018 for left breast and 3.3 vs 17, p = 0.059 for right breast; V10: 2.5 vs 13.6 p = 0.035 for left breast and 1.7 vs 11, p = 0.07 for the right breast.) As for the NTCP, our data point out that IMRT is not always likely to significantly increase the NTCP to OARs.

Conclusions

In HL male patients IMRT seems feasible and accurate while for women HL patients IMRT should be used with caution.

【 授权许可】

   
2012 De Sanctis et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

【 参考文献 】

• [1]Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, Stovall M, Robison LL, Hudson MM: Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011, 117:1806-1816.
• [2]Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, Greffe B, Wolden S, Robison L: Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000, 85:3227-3232.
• [3]Bhatia S, Ramsay NK, Bantle JP, Mertens A, Robison LL: Thyroid Abnormalities after Therapy for Hodgkin's Disease in Childhood. Oncologist 1996, 1:62-67.
• [4]Milano MT, Constine LS, Okunieff P: Normal tissue tolerance dose metrics for radiation therapy of major organs. Semin Radiat Oncol 2007, 17:131-140.
• [5]Yorke ED, Jackson A, Rosenzweig KE, Merrick SA, Gabrys D, Venkatraman ES, Burman CM, Leibel SA, Ling CC: Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2002, 54:329-339.
• [6]Hudson MM, Poquette CA, Lee J, Greenwald CA, Shah A, Luo X, Thompson EI, Wilimas JA, Kun LE, Crist WM: Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol 1998, 16:3592-3600.
• [7]Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Pukkala E, Lynch CF, Pee D, Smith SA, Van’t Veer MB, Joensuu T, Storm H, Stovall M, Jr Boice JD, Gilbert E, Gail MH: Cumulative absolute breast cancer risk for young women treated for Hodgkin Lymhoma. J Natl Cancer Inst. 2005, 97:1428-1437.
• [8]Van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van’t Veer MB, Noordijk EM, Crommelin MA, Aleman BM, Broeks A, Gospodarowicz M, Travis LB, Russell NS: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003, 95:971-980.
• [9]Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, Hall P, Langmark F, Pukkala E, Andersson M, Kaijser M, Joensuu H, Fosså SD, Travis LB: Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007, 25:1489-1497.
• [10]Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010, 363:640-652.
• [11]Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, Meijnders P, Ghalibafian M, Meerwaldt J, Noordijk E: Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006, 79:270-277.
• [12]Kirova YM, Chargari C: Applications of new irradiation modalities in patients with lymphoma: Promises and uncertainties. World J Radiol 2011, 3:66-69.
• [13]Goodman KA, Toner S, Hunt M, Wu EJ, Yahalom J: Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 2005, 62:198-206.
• [14]Nieder C, Schill S, Kneschaurek P, Molls M: Comparison of the three different mediastinal radiotherapy techniques in female patients: impact on heart sparing and dose to the breast. Radiother Oncol 2007, 82:301-307.
• [15]Weber DC, Peguret N, Dipasquale G, Cozzi L: Involved-node and involved-field volumetric modulated arc vs fixed beam intensity- modulated radiotherapy for female patients with early stage supra-diaphragmatic hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys 2009, 75:1578-1586.
• [16]Chera BS, Rodriguez C, Morris CG, Louis D, Yeung D, Li Z, Mendenhall NP: Dosimetric comparison of three different involved nodal irradiation techniques for stage II hodgkin’s lymphoma patients: conventional radiotehrapy, intensity-modulated radiotehrapy and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys 2009, 75:1173-1180.
• [17]Girinsky T, Pichenot C, Beaudre A, Ghalibafian M, Lefkopoulos D: Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with hodgkin’s disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 2006, 64:218-226.
• [18]Cella L, Liuzzi R, Magliulo M, Conson M, Camera L, Salvatore M, Pacelli R: Radiotherapy of large target volume in Hodgkin’s lymphoma: normal tissue sparing capability of forward IMRT versus conventional techniques. Radiation Oncol 2010, 11:5-33.
• [19]Koeck J, Abo-Madyan Y, Lohr F, Stieler F, Kriz J, Mueller RP, Wenz F, Eich HT: Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys 2012, 83:268-276.
• [20]Sripada PV, Tenali SG, Vasudevan M, Viswanadhan S, Sriraman D, Kandasamy R: Hybrid (COPP/ABV) therapy in childhood Hodgkin's disease: a study of 53 cases during 1989-1993 at the Cancer Institute, Madras. Paediatric Hematol Oncol 1995, 4:333-341.
• [21]Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnoni AM, Bonfante V, Musumeci R, Crippa F: Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987, 5:27-37.
• [22]Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995, 31:1341-1346.
• [23]Eich HT, Engenhart-Cabillic R, Hansemann K, Lukas P, Schneeweiss A, Seegenschmiedt H, Skripnitchenko R, Staar S, Willich N, Muller RP: Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11)hodgkin's lymphoma: an analysis of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 2008, 71:1419-1424.
• [24]International Commission on Radiation Units and Measurements: Report no. 50. Prescribing, recording, and reporting photon beam therapy. ICRU, Washington; 1993.
• [25]Lyman JT, Wolbarst AB: Optimization of radiation therapy, III: a method of assessing complications probabilities from dose-volume histograms. Int J Radiat Oncol Biol Phys 1987, 13:103-109.
• [26]Kutcher GJ, Burman C: Calculation of complication probability factors for non-uniform normal tissue irradaiation: the effective volume method. Int J Radiat Oncol Biol Phys 1989, 16:1623-1630.
• [27]Burman C, Kutcher GJ, Emami B, Goiten M: Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 1991, 21:123-135.
• [28]Chronowski GM, Wilder RB, Tucker SL, Ha CS, Younes A, Fayad L, Rodriguez MA, Hagemeister FB, Barista I, Cabanillas F, Cox JD: Analysis of in-field control and late toxicity for adults with early stage Hodgkin’s disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys 2003, 55:36-43.
• [29]Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, DeLaat C, Fossati-Bellani F, Morgan E, Oberlin O, Reaman G, Ruymann FB, Tersak J, Meadows AT, Late Effects Study Group: High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: report from the late effects study group. J Clin Oncol 2003, 21:4386-4394.
• [30]Metzger ML, Hudson MM, Somes GW, Shorr RI, Li CS, Krasin MJ, Shelso J, Pui CH, Howard SC: White race as a risk factor for hypothyroidism after treatment for pediatric Hodgkin’s lymphoma. J Clin Oncol 2006, 24:1516-1521.
• [31]Weber DC, Johanson S, Peguret N, Cozzi L, Olsen DR: Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage Hodgkin lymphoma in female patients. Int J Radiat Oncol Biol Phys 2011, 81:490-497.
• [32]Hall EJ, Wuu CS: Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003, 56:83-88.
• [33]Hall EJ: Intensity modulated radiation therapy, protons, and the risk of second cancer. Int J Radiat Oncol Biol Phys 2006, 65:1-7.
• [34]Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA, Rosen II: The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005, 62:1195-1203.